Cargando…

Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Lung cancer is one of the most common cancers and can be difficult to treat. One of the treatment methods uses drugs that target a protein called the epidermal growth factor receptor, but the results vary from patient to patient. In this research, we used a technique called radiomics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ting-Wei, Hsu, Ming-Sheng, Lin, Yi-Hui, Chiu, Hwa-Yen, Chao, Heng-Sheng, Liao, Chien-Yi, Lu, Chia-Feng, Wu, Yu-Te, Huang, Jing-Wen, Chen, Yuh-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377421/ https://www.ncbi.nlm.nih.gov/pubmed/37509204 http://dx.doi.org/10.3390/cancers15143542

Ejemplares similares

Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients
por: Wang, Ting-Wei, et al.
Publicado: (2023)

A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Lu, Chia-Feng, et al.
Publicado: (2023)

Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors
por: Wang, Ting-Wei, et al.
Publicado: (2023)

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
por: Su, Vincent Yi-Fong, et al.
Publicado: (2020)

The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018)

IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
por: Wu, Shang-Gin, et al.
Publicado: (2019)

Application of Artificial Intelligence in Lung Cancer
por: Chiu, Hwa-Yen, et al.
Publicado: (2022)

Radiomic profiling of clear cell renal cell carcinoma reveals subtypes with distinct prognoses and molecular pathways
por: Lin, Peng, et al.
Publicado: (2021)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

Anchor-based classification and type-C inhibitors for tyrosine kinases
por: Hsu, Kai-Cheng, et al.
Publicado: (2015)

NEAP/DUSP26 suppresses receptor tyrosine kinases and regulates neuronal development in zebrafish
por: Yang, Chi-Hwa, et al.
Publicado: (2017)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis
por: Xue, Jianchao, et al.
Publicado: (2022)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

The Potential of Ultrasound Radiomics in Carpal Tunnel Syndrome Diagnosis: A Systematic Review and Meta-Analysis
por: Wu, Wei-Ting, et al.
Publicado: (2023)

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
por: Chang, Yi-Fang, et al.
Publicado: (2019)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer
por: Liu, Bing, et al.
Publicado: (2016)

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis
por: Deng, Jia, et al.
Publicado: (2023)

Radiomics Analysis for Multiple Myeloma: A Systematic Review with Radiomics Quality Scoring
por: Klontzas, Michail E., et al.
Publicado: (2023)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

The Role of Radiomics in Salivary Gland Imaging: A Systematic Review and Radiomics Quality Assessment
por: Aringhieri, Giacomo, et al.
Publicado: (2022)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis
por: Liao, Chun-Kai, et al.
Publicado: (2022)

Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)
por: Jeong, Soo Young, et al.
Publicado: (2022)

Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2018)

Impact of comorbidities on the prognoses of trauma patients: Analysis of a hospital-based trauma registry database
por: Wang, Chih-Yuan, et al.
Publicado: (2018)

Disruption of Cytosolic Folate Integrity Aggravates Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Modulates Metastatic Properties in Non-Small-Cell Lung Cancer Cells
por: Shen, Po-Wen, et al.
Publicado: (2021)

Multi-View Radiomics Feature Fusion Reveals Distinct Immuno-Oncological Characteristics and Clinical Prognoses in Hepatocellular Carcinoma
por: Gu, Yu, et al.
Publicado: (2023)

Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis
por: Kuo, Meng-Hsuan, et al.
Publicado: (2023)

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
por: Liao, Bin-Chi, et al.
Publicado: (2016)

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
por: Kronick, Olivia, et al.
Publicado: (2023)

Phosphorylation of adducin-1 by cyclin-dependent kinase 5 is important for epidermal growth factor-induced cell migration
por: Su, Chia-Yi, et al.
Publicado: (2019)

Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study
por: Wen, Meng-Jung, et al.
Publicado: (2023)

Radiomics in Urolithiasis: Systematic Review of Current Applications, Limitations, and Future Directions
por: Lim, Ee Jean, et al.
Publicado: (2022)

Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma
por: Zhu, Jing, et al.
Publicado: (2020)

Comparison of Conventional and Radiomic Features between (18)F-FBPA PET/CT and PET/MR
por: Liao, Chien-Yi, et al.
Publicado: (2021)

Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study
por: Li, Chia-Ling, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fh218q236qbjcghad2n5ddmkf1